Results 131 to 140 of about 68,946 (284)

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work‐Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping

American Journal of Hematology, Volume 100, Issue 6, Page 1029-1048, June 2025.
ABSTRACT The latest updates to the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.) and ICC (International Consensus Classification) criteria highlight the critical need for comprehensive and precise cytogenomic data for diagnosis, prognostication, and treatment.
Rashmi Kanagal‐Shamanna, Anna Puiggros, Isabel Granada, Gordana Raca, Katrina Rack, Mar Mallo, Barbara Dewaele, Adam C. Smith, Yassmine Akkari, Brynn Levy, Robert P. Hasserjian, Adela Cisneros, Marta Salido, Guillermo Garcia‐Manero, Hui Yang, M. Anwar Iqbal, Ravindra Kolhe, Francesc Solé, Blanca Espinet   +18 more
wiley   +1 more source

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. [PDF]

, 1995
To determine the functional importance of Ras in transformation by Abl oncogenes, we used a genetic approach to measure the effect of impaired Ras activity on the ability of Bcr-Abl or v-Abl to transform cells.
McLaughlin, J, Sawyers, CL, Witte, ON
core  

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Mountford, J.C.   +4 more
core   +1 more source

Phyladelphia positive acute lymphoblastic leukemia [PDF]

, 2008
O cromossomo Filadélfia (Ph1) é a alteração citogenética mais comum da Leucemia Linfoblástica Aguda do adulto (LLA). Esta alteração citogenética predomina nos adultos com mais de 50 anos e na LLA de origem na célula B, principalmente CD10 positiva.
SCHAFFEL, Rony, SIMÕES, Belinda P.
core   +1 more source

Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies

The Scientific World Journal, 2006
Imatinib (Gleevec/STI-571/CGP57148B, Novartis) is a small-molecule, tyrosine kinase inhibitor developed to target BCR-ABL, c-Kit, and PDGF-R. Through inhibition of these oncogenic kinases, imatinib is effective in the treatment of BCR-ABL–positive ...
Michael R. Burgess, Charles L. Sawyers
doaj   +1 more source

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia [PDF]

, 2008
The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CML) and is the standard front-line therapy for patients in chronic phase.
Anderson S M, Baccarani M, Bedi A, Cortes J, Danhauser-Riedl S, Dombret H, Donato N J, Druker B J, Engelman A, Gambacorti C, Hochhaus A, Ilaria R L, Kantarjian H M, Kieslinger M, Larson R, Lee F Y, Martinelli G, Nagar B, Overell R W, Pear W S, Puil L, Quintas-Cardama A, Shaoguang Li, Talpaz M, Watson J D   +24 more
core   +2 more sources

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

Molecular Cancer, 2007
Background Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia.
Groffen John, Pertz Veerle, Müschen Markus, Trageser Daniel, Zhang Bin, Feldhahn Niklas, Kaur Pavinder, Heisterkamp Nora   +7 more
doaj   +1 more source

Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells. [PDF]

Iran J Basic Med Sci, 2023
Kamyabi R, Jahandideh A, Panahi N, Muhammadnejad S.   +3 more
europepmc   +1 more source

Impaired DNA replication within progenitor cell pools promotes leukemogenesis. [PDF]

, 2005
Impaired cell cycle progression can be paradoxically associated with increased rates of malignancies. Using retroviral transduction of bone marrow progenitors followed by transplantation into mice, we demonstrate that inhibition of hematopoietic ...
Ames, Anderson, Andriy Marusyk, Begg, Blagosklonny, Calabretta, Castor, Chang, Choi, Christensen, Christopher C Porter, Christopher Kemp, DeGregori, Dimova, Field, Furgerson, Ganna Bilousova, Gottlieb, Greaves, Hanahan, Hariharan, Jacks, James DeGregori, Jamieson, Just, Kinder, Li, Li, Lightfoot, Lin, Luch, Lundin, Matioli, Milner, Murga, Passegue, Pear, Penit, Pui, Robert D Cardiff, Ryan, Saintigny, Sawyers, Schaefer, Shechter, Sirard, Skibola, Skorski, Spangrude, Sterkers, Van Etten, Wallace-Brodeur, Wong, Wu, Yamasaki, Zhang, Zhu, Zimmerman   +57 more
core   +3 more sources